EUROPEAN: bourses moved up and down during the reporting week to February 13, with a particularly strong showing on February 9, when a batch of good earnings reports boosted markets. The best-performing market was FRANKFURT, where Schwarz leapt 12.3%, after Dresdner Kleinwort Wasserstein initiated coverage of the firm at buy with a 72-euros price target, saying the second quarter figures should alert the market to the full potential of the company's Phase III products. Bayer was lower early in the period, on continued worries about its drug Trasylol (aprotinin; see page 20), but recovered later for a week-on-week gain of 1.8%. AMSTERDAM witnessed a 7.3% gain for Akzo Nobel, after the firm posted better-than-expected 2005 results and the news that it plans to float its drug unit (Marketletter February 13).
LONDON: saw good performance for little Acambis, which rose 8.9% on no particular news. Drug majors AstraZeneca and GlaxoSmithKline went in opposite directions, with the former declining 1.3% and the later up 3.7%, as investors continued to favor GSK because of its strong R&D pipeline. The news that AstraZeneca was withdrawing its controversial drug Exanta (ximelagatran; see page 19), came too late to impact its share price. Provalis fell back 8.6%, after announcing it would sell certain assets to Kogen (Marketletter February 6). SkyePharma, which has seen a great deal of volatility of late, moved 6.0% higher on the last reporting day, on the news that its ousted founder, Ian Gowrie-Smith had moved forward his departure. However, investor activists are still pushing for an Extraordinary General Meeting.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
A clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases.
Stock Commentary - Europe - week to Feb 13, 2006
EUROPEAN: bourses moved up and down during the reporting week to February 13, with a particularly strong showing on February 9, when a batch of good earnings reports boosted markets. The best-performing market was FRANKFURT, where Schwarz leapt 12.3%, after Dresdner Kleinwort Wasserstein initiated coverage of the firm at buy with a 72-euros price target, saying the second quarter figures should alert the market to the full potential of the company's Phase III products. Bayer was lower early in the period, on continued worries about its drug Trasylol (aprotinin; see page 20), but recovered later for a week-on-week gain of 1.8%. AMSTERDAM witnessed a 7.3% gain for Akzo Nobel, after the firm posted better-than-expected 2005 results and the news that it plans to float its drug unit (Marketletter February 13).
LONDON: saw good performance for little Acambis, which rose 8.9% on no particular news. Drug majors AstraZeneca and GlaxoSmithKline went in opposite directions, with the former declining 1.3% and the later up 3.7%, as investors continued to favor GSK because of its strong R&D pipeline. The news that AstraZeneca was withdrawing its controversial drug Exanta (ximelagatran; see page 19), came too late to impact its share price. Provalis fell back 8.6%, after announcing it would sell certain assets to Kogen (Marketletter February 6). SkyePharma, which has seen a great deal of volatility of late, moved 6.0% higher on the last reporting day, on the news that its ousted founder, Ian Gowrie-Smith had moved forward his departure. However, investor activists are still pushing for an Extraordinary General Meeting.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
Become a subscriber
£820
Or £77 per month
Chairman, Sanofi Aventis UK
Companies featured in this story
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze